These medtech companies raised the most VC last year

Share

8 (tied). ImmusanT

Cambridge, Mass.
Venture capital raised: $40 million

immusant-logo

ImmusanT raised $40 million in venture capital during its expansion stage of development in the fourth quarter of 2017, according to the MoneyTree Report. This is the company’s third investment sequence and investors include ARCH Venture Partners and Vatera Healthcare Partners.

ImmusanT is working to increase tolerance to gluten in people who have celiac disease. The company is improving diagnosis and treatment by harnessing new discoveries in immunology. ImmusanT is developing a therapeutic vaccine for celiac disease called Nexvax2, as well as a diagnostic and monitoring tool to improve management of the disease.

Next >>

Want to stay on top of MDO content? Subscribe to our e-newsletter.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Speak Your Mind

*